|
| 37890117 | Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. | J Clin Oncol | 2024 |
| 38062123 | Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232. | Leukemia | 2024 |
| 36256911 | Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study. | J Clin Oncol | 2023 |
| 37489549 | Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia. | Pediatr Blood Cancer | 2023 |
| 37961674 | Identification and targeting of treatment resistant progenitor populations in T-cell Acute Lymphoblastic Leukemia. | Res Sq | 2023 |
| 37592363 | Assessment of proxy-reported responses as predictors of motor and sensory peripheral neuropathy in children with B-lymphoblastic leukemia. | Pediatr Blood Cancer | 2023 |
| 37556734 | Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. | Blood | 2023 |
| 37553297 | Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1). | Pediatr Blood Cancer | 2023 |
| 37702960 | Hemophagocytic lymphohistiocytosis and clonally related T-cell malignancies in a pediatric patient. | Pediatr Blood Cancer | 2023 |
| 37944074 | Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay. | JCO Precis Oncol | 2023 |
| 37503171 | Germline Genetic <i>NBN</i> Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children. | Res Sq | 2023 |
| 37601850 | SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731. | EJHaem | 2023 |
| 35500285 | CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. | Blood Adv | 2023 |
| 35484682 | Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. | Haematologica | 2023 |
| 37259259 | Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631. | Pediatr Blood Cancer | 2023 |
| 37257143 | Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. | J Clin Oncol | 2023 |
| 37157018 | Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. | Leukemia | 2023 |
| 37019972 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | Nat Commun | 2023 |
| 37407142 | Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. | Lancet Haematol | 2023 |
| 37001051 | Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. | Blood | 2023 |
| 36966262 | Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. | Leukemia | 2023 |
| 36725118 | Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. | Lancet Haematol | 2023 |
| 36576946 | Identification of TCF3 germline variants in pediatric B-cell acute lymphoblastic leukemia. | Blood Adv | 2023 |
| 36739480 | Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia. | Mol Ther | 2023 |
| 36603187 | Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report. | Blood | 2023 |
| 36821772 | Impact of vincristine-steroid pulses during maintenance for B-cell pediatric ALL: a systematic review and meta-analysis. | Blood | 2023 |
| 36700399 | Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia. | Haematologica | 2023 |
| 36108304 | Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. | Blood | 2023 |
| 36309560 | Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group. | Leukemia | 2023 |
| 36332176 | EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy. | Blood | 2023 |
| 36380143 | Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. | Leukemia | 2023 |
| 36325891 | Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia. | Haematologica | 2023 |
| 33375775 | Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. | Haematologica | 2022 |
| 35411095 | JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. | Leukemia | 2022 |
| 35767897 | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. | Blood | 2022 |
| 35575404 | Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia. | J Natl Cancer Inst | 2022 |
| 35788692 | MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. | Neuro Oncol | 2022 |
| 35552709 | Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. | J Natl Cancer Inst | 2022 |
| 36580335 | Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia. | JAMA Netw Open | 2022 |
| 36042365 | Clinical parameter-based prediction of DNA methylation classification generates a prediction model of prognosis in patients with juvenile myelomonocytic leukemia. | Sci Rep | 2022 |
| 36130297 | Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. | Blood | 2022 |
| 35984649 | Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia. | Cancer Discov | 2022 |
| 36050548 | The genomic landscape of pediatric acute lymphoblastic leukemia. | Nat Genet | 2022 |
| 36083863 | Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2022 |
| 35007127 | Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. | J Clin Oncol | 2022 |
| 35271306 | Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. | J Clin Oncol | 2022 |
| 35115686 | Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. | Nat Genet | 2022 |
| 35201611 | Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. | Cancer | 2022 |
| 35172563 | Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. | Haematologica | 2022 |
| 35084434 | Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. | JAMA Oncol | 2022 |